{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:19:48Z","timestamp":1789654788578,"version":"4.0.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/inf.0000000000000516","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T13:15:37Z","timestamp":1410441337000},"page":"186-194","source":"Crossref","is-referenced-by-count":57,"title":["Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine"],"prefix":"10.1097","volume":"34","author":[{"given":"Ajoke","family":"Sobanjo-ter Meulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo A.","family":"Malacaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"McFetridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio D.","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwy K.","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/595857","article-title":"Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.","volume":"48","author":"Richter","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.vaccine.2012.01.091","article-title":"The relationship between pneumococcal serotypes and antibiotic resistance.","volume":"30","author":"Song","year":"2012","journal-title":"Vaccine"},{"issue":"suppl 1","key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002512-199915001-00003","article-title":"Pneumococcal vaccination for older adults: the first 20 years.","volume":"15","author":"Fedson","year":"1999","journal-title":"Drugs Aging"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14787210.6.5.619","article-title":"Antimicrobial-resistant Streptococcus pneumoniae: trends and management.","volume":"6","author":"Jacobs","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States.","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.","volume":"374","author":"OBrien","year":"2009","journal-title":"Lancet"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Active Bacterial Core SurveillanceEmerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1086\/521626","article-title":"Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.","volume":"196","author":"Hicks","year":"2007","journal-title":"J Infect Dis"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1016\/j.vaccine.2012.04.021","article-title":"Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine.","volume":"30","author":"Elberse","year":"2012","journal-title":"Vaccine"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates.","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum.","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R16-16-20210202","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/erv.11.14","article-title":"Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.","volume":"10","author":"Blanchard-Rohner","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/597388","article-title":"Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.","volume":"199","author":"Madhi","year":"2009","journal-title":"J Infect Dis"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/CVI.00062-10","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.","volume":"17","author":"Esposito","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R28-16-20210202","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"006 Study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/erv.11.76","article-title":"Review on the immunogenicity and safety of PCV-13 in infants and toddlers.","volume":"10","author":"Nunes","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R30-16-20210202","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1016\/j.vaccine.2011.10.012","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants.","volume":"29","author":"Grimprel","year":"2011","journal-title":"Vaccine"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/INF.0b013e3182372c6a","article-title":"3011 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.","volume":"30","author":"Frenck","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1442-200X.2003.01706.x","article-title":"Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine.","volume":"45","author":"Kanra","year":"2003","journal-title":"Pediatr Int"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/323648","article-title":"Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.","volume":"184","author":"Wuorimaa","year":"2001","journal-title":"J Infect Dis"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1016\/j.vaccine.2005.06.023","article-title":"Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine.","volume":"23","author":"Wuorimaa","year":"2005","journal-title":"Vaccine"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.inf.0000050459.74134.d5","article-title":"Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.","volume":"22","author":"Puumalainen","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R36-16-20210202","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:05:14Z","timestamp":1620954314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201502000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000516","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}